BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35657573)

  • 1. Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
    Kunimasa K; Sugimoto N; Tamiya M; Inoue T; Kawamura T; Kanzaki R; Okami J; Nishino K
    Invest New Drugs; 2022 Oct; 40(5):1137-1140. PubMed ID: 35657573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations.
    Okauchi S; Satoh H
    Invest New Drugs; 2022 Dec; 40(6):1354-1355. PubMed ID: 36152106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
    Cortiula F; Pelizzari G; Corvaja C; De Maglio G; Fasola G
    Anticancer Drugs; 2022 Oct; 33(9):960-962. PubMed ID: 35979997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
    Cheng WC; Lin CC; Liao WC; Lin YC; Chen CH; Chen HJ; Tu CY; Hsia TC
    BMC Cancer; 2024 Feb; 24(1):228. PubMed ID: 38373960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.
    Morita A; Hosokawa S; Yamada K; Umeno T; Kano H; Kayatani H; Shiojiri M; Sakugawa M; Bessho A
    Thorac Cancer; 2021 Apr; 12(8):1248-1251. PubMed ID: 33651475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
    Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
    Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
    Chiba S; Akiyama M; Yakuwa K; Sato H; Hirano K; Utsumi Y; Nagashima H; Sugai T; Maemondo M
    Ann Palliat Med; 2022 Aug; 11(8):2745-2750. PubMed ID: 34806395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
    Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
    Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
    Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944068
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations.
    Wells L; Qin A
    Curr Treat Options Oncol; 2023 Dec; 24(12):1802-1814. PubMed ID: 38095779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
    Oashi A; Yasuda H; Kobayashi K; Tani T; Hamamoto J; Masuzawa K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
    Mol Cancer Ther; 2019 Sep; 18(9):1593-1601. PubMed ID: 31253648
    [No Abstract]   [Full Text] [Related]  

  • 15. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
    Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
    Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
    Tamura T; Kawakado K; Makimoto G; Nakanishi M; Kuyama S
    Thorac Cancer; 2021 Jun; 12(11):1770-1774. PubMed ID: 33942527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    Han C; Ding X; Li M; Luo N; Qi Y; Wang C
    J Cancer Res Clin Oncol; 2022 May; 148(5):1265-1268. PubMed ID: 35230510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
    Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.